Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283057 | 0.88 | CA1 (0.42) | CA1CA2CA12CA9NAMPT | |
| SCHEMBL6284054 | 0.82 | RAB9A (0.42) | CA1CA2NAMPTMAPT | |
| SCHEMBL6286884 | 0.81 | CYP3A4 (0.45) | CA1CA2NAMPTMAPTNPSR1 | |
| SCHEMBL6291032 | 0.80 | CA1 (0.39) | CA1CA2CA12CA9NAMPT | |
| SCHEMBL6287122 | 0.80 | CA1 (0.41) | CA1CA2CA12CA9NAMPT | |
| SCHEMBL6290355 | 0.79 | CTSS (0.46) | TDP1MAPTPTPN1 | |
| SCHEMBL6287033 | 0.79 | CA1 (0.48) | CA1CA2CA12CA9NAMPT | |
| SCHEMBL6287974 | 0.78 | KMT2A (0.43) | CA1CA2TDP1MAPTNPSR1 | |
| SCHEMBL6286738 | 0.78 | KMT2A (0.43) | CA1CA2TDP1MAPTNPSR1 | |
| SCHEMBL6287996 | 0.78 | CTSL (0.41) | CA1CA2ACHETDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | CA1 4805/4885CA2 4718/4885CA12 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.